Can-Fite BioPharma (NYSE:CANF) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of Can-Fite BioPharma (NYSE:CANF) from a hold rating to a sell rating in a research note released on Friday.

A number of other equities research analysts have also weighed in on CANF. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Can-Fite BioPharma in a research report on Thursday, December 5th. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Can-Fite BioPharma in a report on Tuesday, November 12th.

Can-Fite BioPharma Price Performance

Shares of CANF stock opened at $1.58 on Friday. The company has a market capitalization of $5.59 million, a P/E ratio of -0.88 and a beta of 1.32. The company’s 50-day simple moving average is $2.15 and its two-hundred day simple moving average is $2.47. Can-Fite BioPharma has a one year low of $1.29 and a one year high of $4.69.

Hedge Funds Weigh In On Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC boosted its position in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the quarter. Armistice Capital LLC owned approximately 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent reporting period. 21.00% of the stock is owned by institutional investors.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.